Get access

Harnessing the beneficial properties of adipogenic microbes for improving human health


  • United States Patents approved: Patent number 6,127,113. Viral Obesity methods and Compositions. Patent number 6,664,050. Viral Obesity methods and Compositions. Patent number U.S. 8,008,436B2, dated 30 August 2011: Adenovirus 36 E4orf1 gene and protein and their uses.
  • Patent filed: Dhurandhar NV and Holland TC. Ad-36 E4 orf-1, E1A and obesity and diabetes.

    November 2006. File no. 05P09. Adenovirus Ad36 E4orf1 protein for prevention and treatment of non-alcoholic fatty liver disease. U.S. patent application 8 July 2010. 61/362,443; Taiwan.

    Patent number 100124173. Enhanced glycaemic control using Ad36E4orf1 and AKT1 Inhibitor. January 2013.

  • Provisional Patent filed: 17 October 2010. 61/714,899. Compositions and Methods for Improving Glucose Uptake.

Address for correspondence: Dr Nikhil V. Dhurandhar, Infections and Obesity Laboratory, Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA 70808, USA.


Prof. Patrice D. Cani, Metabolism and Nutrition Research Group, WELBIO (Walloon Excellence in Life Sciences and BIOtechnology), Louvain Drug Research Institute, Université catholique de Louvain, Av. E. Mounier, 73, B1.73.11, 1200 Bruxelles, Belgium.



Obesity is associated with numerous metabolic comorbidities. Weight loss is an effective measure for alleviating many of these metabolic abnormalities. However, considering the limited success of most medical weight-management approaches in producing a sustained weight loss, approaches that improve obesity-related metabolic abnormalities independent of weight loss would be extremely attractive and of practical benefit. Metabolically healthy obesity supports the notion that a better metabolic profile is possible despite obesity. Moreover, adequate expansion of adipose tissue appears to confer protection from obesity-induced metabolic comorbidities. To this end, the 10th Stock conference examined new approaches to improve metabolic comorbidities independent of weight loss. In particular, human adenovirus 36 (Ad36) and specific gut microbes were examined for their potential to influence lipid and glucose homeostasis in animals and humans. While these microbes possess some undesirable properties, research has identified attributes of adenovirus Ad36 and gut microbes that may be selectively harnessed to improve metabolic profile without the obligatory weight loss. Furthermore, identifying the host signalling pathways that these microbes recruit to improve the metabolic profile may offer new templates and targets, which may facilitate the development of novel treatment strategies for obesity-related metabolic conditions.